A secondary concern of breast cancer is the risk of the cancer cells spreading to the bones, causing severe pain and affecting quality of life. But, a new study has identified how bones get damaged and researchers from Huntsman Cancer Institute at the University of Utah are developing a new drug to mitigate this problem.
There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
The US Food and Drug Administration has accepted the first Biologics License Application for durvalumab (MEDI4736) to treat patients with urothelial cancer (UC) for whom cisplatin failed to stop disease progression.
One of the complications of multiple myeloma, a malignancy of plasma cells in the bone marrow, includes bone fractures and/or spinal cord compression. But a new treatment may offer bone protection to mitigate these issues.
A supplemental New Drug Application has been submitted to the US Food and Drug Administration for marginal zone lymphoma (MZL), and if approved, ibrutinib (Imbruvica) will be the first therapy specifically approved for patients with MZL.
Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.